Inbunden, Engelska, 2020
Second Generation Cell and Gene-Based Therapies
Biological Advances, Clinical Outcomes and Strategies for Capitalisation
Av Alain Vertes, Nathan J. Dowden, Devyn Smith, Nasib Qureshi
1700 kr
Beställningsvara. Skickas inom 11-20 vardagar. Fri frakt över 249 kr.
Beskrivning
- Helps readers learn about the most current trends in cell-based therapy, their overall effectiveness from a clinical prospective, and how the industry is moving therapies forward for capitalization
- "Perspectives" section at the end of each chapter summarizes key learnings, hypotheses, and objectives highlighted and combines scientific and business insights
- Edited and authored by scientists representing both basic and clinical research and industry, presenting a complete story of the current state and future promise of cellular therapies
Produktinformation
- Utgivningsdatum: 2020-02-10
- Mått: 191 x 235 x 47 mm
- Vikt: 1 860 g
- Format: Inbunden
- Språk: Engelska
- Antal sidor: 846
- Förlag: Elsevier Science
- ISBN: 9780128120347
Utforska kategorier
Mer om författaren
University of Illinois at Urbana-Champaign, Institut Pasteur Paris, and University of Lille Flanders-Artois• Sloan Fellow from London Business School and a microbiologist by training (University of Illinois at Urbana-Champaign, Institut Pasteur Paris, and University of Lille Flandres-Artois). • Consulting, Partnering & Fund Raising, Founder, Managing Director, NxR Biotechnologies, Switzerland.• Dr. Vertès is a strategy and business development consultant for cell therapeutic biotech companies, and works to enable seed funding in the field. Focusing on technology deployment and innovation commercialization, he has contributed to both industrial and pharmaceutical biotechnology, in different functions including research, manufacturing, contract research, and strategic alliances in pharmaceuticals (Lilly, Pfizer, Roche). • Championed radical innovation for bringing to patients disease-modifying, paradigm-changing therapeutics such as siRNA, and led in a scientific and business manner Roche’s global cell therapeutics strategy and implementation team resulting in Roche’s entry in 2010 in the field of regenerative medicine.• Member, Industry Committee-Europe, Tissue Engineering and Regenerative Medicine International Society• Co-Editor, Stem Cells in Regenerative Medicine: Science, Regulation and Business Strategies (Wiley, 2015). • Head of Operations & Strategy, Medicinal Sciences Division of R&D, Pfizer Inc.• Responsible for all cell & gene therapy products, as well as previously developing Pfizer’s Regenerative Medicine program.• PhD in Genetics from Harvard Medical School.• Adjunct faculty member at Northeastern University. Research Chemical/Biochemical Engineer, United States Department of Agriculture (USDA), Agricultural Research Service (ARS), National Center for Agricultural Utilization Research (NCAUR), Peoria, IL, USA.PhD (Chemical/Biological Engineering), PhD (Fermentation Technology)Fellow in American Institute of Chemical Engineers (AIChE), Society for Industrial Microbiology & Biotechnology (SIMB), and American Institute of Chemists (AIC).Co-Editor, Stem cells in Regenerative Medicine (Wiley, 2015)
Betyg & recensioner
0 recensioner
Inga recensioner tillgängliga.